The steady rise in antibiotic-resistant bacteria is creating a global healthcare crisis. Fatalities from hospital-acquired infections (HAIs) are more than double those from auto accidents in the US. To address the problem, Congress appropriated $160 million in new investments for the CDC to fight antibiotic resistance in 2016. That appropriation has grown each year.
Supported by the CDC and other organizations, many hospitals have instituted Antibiotic Stewardship Programs (ASP). These programs are designed to engage the broad expertise of the hospital to better support clinicians and their use of antibiotics. With the goal of getting the “right drug” for the “right bug”, a successful antibiotic stewardship program includes the commitment of leadership to invest the proper resources, as well as tracking and accountability and leveraging internal drug expertise.
Several articles and presentations highlight the savings and improved patient outcomes that result from a strong ASP program.
- Shorter courses of therapy
- Reduced length of stay of patients
- Increased patient safety
- Reduced risk of HAI (Hospital-Acquired infections)
In many cases, an antibiotic stewardship program not only improves patient outcomes but can have an impact on the cost of health care, with some estimates that ASP programs can reduce antibiotic use between 20 – 30% and save small and large hospitals between $200,000 and $900,000 per year.
The process improvements and efficiencies of ASPs are evident. but limited by current antibiotic susceptibility testing (AST) methods which take 24-72 hours for results. To fully address the antibiotic resistance problem, diagnostic technology supporting hospitals and clinics must evolve, accelerate and improve.
First Light Diagnostics’ MultiPath™ platform represents a quantum leap in AST testing. With results in 4 hours, MultiPath will deliver invaluable data to clinicians and will allow them to determine the optimal, personalized therapy for their patients. In many cases, this means a targeted antibiotic versus the broad spectrum antibiotics used today.
With the MultiPath platform, hospitals will be able to realize greater gains in targeted antibiotic use, reductions in length of stay and reduced risk in HAI’s far beyond what ASP programs can deliver today.
To learn more about First Light Diagnostics’ industry-changing diagnostic platform, visit www.firstlightdx.com.